

# Kenneth K Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3428031/publications.pdf>

Version: 2024-02-01

217  
papers

14,080  
citations

31902

53  
h-index

21474

114  
g-index

221  
all docs

221  
docs citations

221  
times ranked

6623  
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus. American Journal of Gastroenterology, 2008, 103, 788-797.	0.2	1,348
2	Radiofrequency Ablation in Barrett's Esophagus with Dysplasia. New England Journal of Medicine, 2009, 360, 2277-2288.	13.9	1,348
3	A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop 1 1 Members of the workshop composed a group of international experts in BE from gastroenterology, surgery, pathology, molecular biology, outcomes, and epidemiology. Conference chairman: Prateek Sharma; conference moderator: Kenneth McQuaid; group leaders: John Dent, M. Brian Fennerty, Richard Sampliner, Stuart Spechler; participants: Alan Cameron, Douglas Corley, Gary Falk, John Goldblum, John Hunter, Japustila. Gastroenterology, 2004, 127, 310-330.	0.6	579
4	Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointestinal Endoscopy, 2005, 62, 488-498.	0.5	503
5	Durability of Radiofrequency Ablation in Barrett's Esophagus With Dysplasia. Gastroenterology, 2011, 141, 460-468.	0.6	432
6	Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology, 2001, 120, 1630-1639.	0.6	419
7	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell, 2018, 33, 721-735.e8.	7.7	396
8	Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointestinal Endoscopy, 2007, 66, 460-468.	0.5	338
9	Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology, 2002, 122, 1101-1112.	0.6	334
10	Endoscopic and Surgical Treatment of Mucosal (T1a) Esophageal Adenocarcinoma in Barrett's Esophagus. Gastroenterology, 2009, 137, 815-823.	0.6	329
11	Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients (with video). Gastrointestinal Endoscopy, 2007, 65, 185-195.	0.5	292
12	Long-Term Survival Following Endoscopic and Surgical Treatment of High-Grade Dysplasia in Barrett's Esophagus. Gastroenterology, 2007, 132, 1226-1233.	0.6	271
13	Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointestinal Endoscopy, 2010, 71, 680-685.	0.5	262
14	Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus. Gastrointestinal Endoscopy, 2000, 52, 328-332.	0.5	256
15	Recurrence of Esophageal Intestinal Metaplasia After Endoscopic Mucosal Resection and Radiofrequency Ablation of Barrett's Esophagus: Results From a US Multicenter Consortium. Gastroenterology, 2013, 145, 79-86.e1.	0.6	222
16	Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointestinal Endoscopy, 2001, 54, 682-688.	0.5	214
17	A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus. Cancer Research, 2009, 69, 4112-4115.	0.4	202
18	Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. Gastrointestinal Endoscopy, 2008, 68, 867-876.	0.5	193

#	ARTICLE	IF	CITATIONS
19	AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2020, 158, 1776-1786.	0.6	188
20	History, Molecular Mechanisms, and Endoscopic Treatment of Barrett's Esophagus. <i>Gastroenterology</i> , 2010, 138, 854-869.	0.6	181
21	Bone Morphogenetic Protein 4 Expressed in Esophagitis Induces a Columnar Phenotype in Esophageal Squamous Cells. <i>Gastroenterology</i> , 2007, 132, 2412-2421.	0.6	153
22	Endoscopic Tri-Modal Imaging Is More Effective Than Standard Endoscopy in Identifying Early-Stage Neoplasia in Barrett's Esophagus. <i>Gastroenterology</i> , 2010, 139, 1106-1114.e1.	0.6	149
23	Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2016, 150, 599-607.e7.	0.6	144
24	Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. <i>Gastroenterology</i> , 2000, 119, 624-630.	0.6	135
25	Development of Subsquamous High-Grade Dysplasia and Adenocarcinoma After Successful Radiofrequency Ablation of Barrett's Esophagus. <i>Gastroenterology</i> , 2012, 143, 564-566.e1.	0.6	128
26	Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 252-257.	2.4	123
27	Initial results using low-dose photodynamic therapy in the treatment of Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , 1995, 42, 59-63.	0.5	121
28	The Effect of Selective Cyclooxygenase-2 Inhibition in Barrett's Esophagus Epithelium: An In Vitro Study. <i>Journal of the National Cancer Institute</i> , 2002, 94, 422-429.	3.0	115
29	Comparative diagnostic performance of volumetric laser endomicroscopy and confocal laser endomicroscopy in the detection of dysplasia associated with Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 880-888.e2.	0.5	110
30	Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 252-257.	2.4	108
31	Late Recurrence of Barrett's Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report From Ablation in Intestinal Metaplasia Containing Dysplasia Trial. <i>Gastroenterology</i> , 2017, 153, 681-688.e2.	0.6	99
32	Factors Associated With Progression of Barrett's Esophagus: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1046-1055.e8.	2.4	97
33	Risk of recurrence of Barrett's esophagus after successful endoscopic therapy. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 1090-1106.e3.	0.5	94
34	Safety and feasibility of volumetric laser endomicroscopy in patients with Barrett's esophagus (with Tj ETQq0 0.0 rgBT /Overlock 10	0.5	93
35	A Randomized Comparative Effectiveness Trial of Novel Endoscopic Techniques and Approaches for Barrett's Esophagus Screening in the Community. <i>American Journal of Gastroenterology</i> , 2015, 110, 148-158.	0.2	92
36	Significance of Neoplastic Involvement of Margins Obtained by Endoscopic Mucosal Resection in Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2007, 102, 2380-2386.	0.2	91

#	ARTICLE	IF	CITATIONS
37	Current status of photodynamic therapy of Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , 1999, 49, S20-S23.	0.5	89
38	Increased detection of Barrett's esophagus-associated neoplasia using wide-area trans-epithelial sampling: a multicenter, prospective, randomized trial. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 348-355.	0.5	87
39	Predictors of stricture formation after photodynamic therapy for high-grade dysplasia in Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , 2007, 65, 60-66.	0.5	86
40	American Gastroenterological Association Technical Review on the Role of the Gastroenterologist in the Management of Esophageal Carcinoma. <i>Gastroenterology</i> , 2005, 128, 1471-1505.	0.6	78
41	Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model. <i>Cancer</i> , 1998, 82, 421-427.	2.0	77
42	Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia. <i>Gastroenterology</i> , 2015, 149, 567-576.e3.	0.6	77
43	Utility of Biomarkers in Prediction of Response to Ablative Therapy in Barrett's Esophagus. <i>Gastroenterology</i> , 2008, 135, 370-379.	0.6	76
44	A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus. <i>Human Pathology</i> , 2008, 39, 1128-1135.	1.1	73
45	Timeline and location of recurrence following successful ablation in Barrett's oesophagus: an international multicentre study. <i>Gut</i> , 2019, 68, 1379-1385.	6.1	73
46	Obstructive Sleep Apnea Is a Risk Factor for Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 583-588.e1.	2.4	70
47	Use of probe-based confocal laser endomicroscopy (pCLE) in gastrointestinal applications. A consensus report based on clinical evidence. <i>United European Gastroenterology Journal</i> , 2015, 3, 230-254.	1.6	69
48	Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts. <i>Gastroenterology</i> , 2018, 155, 1720-1728.e4.	0.6	67
49	Breath Testing for Barrett's Esophagus Using Exhaled Volatile Organic Compound Profiling With an Electronic Nose Device. <i>Gastroenterology</i> , 2017, 152, 24-26.	0.6	63
50	Gains and Amplifications of <i>c-myc</i> , <i>EGFR</i> , and <i>20.q13</i> Loci in the No Dysplasia to Adenocarcinoma Sequence of Barrett's Esophagus. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1380-1385.	1.1	60
51	Highly Discriminant Methylated DNA Markers for the Non-endoscopic Detection of Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2018, 113, 1156-1166.	0.2	58
52	Safety of Prior Endoscopic Mucosal Resection in Patients Receiving Radiofrequency Ablation of Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 150-154.	2.4	57
53	Cryotherapy for persistent Barrett's esophagus after radiofrequency ablation: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 1396-1404.e1.	0.5	56
54	Screening for Barrett's Esophagus. <i>Gastroenterology</i> , 2015, 148, 912-923.	0.6	54

#	ARTICLE	IF	CITATIONS
55	The Development of a Fluorescence in Situ Hybridization Assay for the Detection of Dysplasia and Adenocarcinoma in Barrett's Esophagus. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 260-267.	1.2	53
56	Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus. <i>Oncotarget</i> , 2017, 8, 203-214.	0.8	53
57	Biomarkers in Barrett Esophagus. <i>Mayo Clinic Proceedings</i> , 2001, 76, 438-446.	1.4	52
58	American Gastroenterological Association Medical Position Statement: Role of the Gastroenterologist in the Management of Esophageal Carcinoma. <i>Gastroenterology</i> , 2005, 128, 1468-1470.	0.6	50
59	Inter-Observer Agreement among Pathologists Using Wide-Area Transepithelial Sampling With Computer-Assisted Analysis in Patients With Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2015, 110, 1257-1260.	0.2	50
60	Combined Celiac Ganglia and Plexus Neurolysis Shortens Survival, Without Benefit, vs Plexus Neurolysis Alone. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 728-738.e9.	2.4	49
61	Notch Signaling Mediates Differentiation in Barrett's Esophagus and Promotes Progression to Adenocarcinoma. <i>Gastroenterology</i> , 2020, 159, 575-590.	0.6	49
62	Impact of celiac neurolysis on survival in patients with pancreatic cancer. <i>Gastrointestinal Endoscopy</i> , 2015, 82, 46-56.e2.	0.5	48
63	Mechanisms of Disease: carcinogenesis in Barrett's esophagus. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2004, 1, 106-112.	1.7	47
64	Photodynamic Therapy for Gastrointestinal Cancer. <i>Photochemistry and Photobiology</i> , 2020, 96, 517-523.	1.3	47
65	Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , 2014, 80, 71-77.	0.5	44
66	Diagnosing gastrointestinal illnesses using fecal headspace volatile organic compounds. <i>World Journal of Gastroenterology</i> , 2016, 22, 1639.	1.4	44
67	Combinatorial Chemoprevention Reveals a Novel Smoothed-Independent Role of GLI1 in Esophageal Carcinogenesis. <i>Cancer Research</i> , 2010, 70, 6787-6796.	0.4	42
68	Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 252-7.	2.4	42
69	International, multicenter, partially blinded, randomised study of the efficacy of photodynamic therapy (PDT) using porfimer sodium (POR) for the ablation of high-grade dysplasia (HGD) in Barrett's esophagus (BE): Results of 24-month follow-up. <i>Gastroenterology</i> , 2003, 124, A20.	0.6	41
70	AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 416-423.	0.5	41
71	Epidemiology and Outcomes of Young-Onset Esophageal Adenocarcinoma: An Analysis from a Population-Based Database. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 142-149.	1.1	40
72	Effects of Autofluorescence Imaging on Detection and Treatment of Early Neoplasia in Patients With Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 774-781.	2.4	39

#	ARTICLE	IF	CITATIONS
73	Clinical and Histologic Determinants of Mortality for Patients With Barrett's Esophagus-Related T1 Esophageal Adenocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 658-664.e3.	2.4	39
74	EUS-guided verteporfin photodynamic therapy for pancreatic cancer. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 179-186.	0.5	39
75	Endoscopic mucosal resection. <i>Gastrointestinal Endoscopy</i> , 2000, 52, 860-863.	0.5	37
76	Photodynamic therapy in Barrett's esophagus. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2003, 13, 483-489.	0.6	37
77	Endoscopic mucosal resection and endoscopic submucosal dissection in esophageal and gastric cancers. <i>Current Opinion in Gastroenterology</i> , 2010, 26, 1.	1.0	37
78	Distinct Role of Kruppel-like Factor 11 in the Regulation of Prostaglandin E2 Biosynthesis. <i>Journal of Biological Chemistry</i> , 2010, 285, 11433-11444.	1.6	37
79	Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2020, 91, 3-10.e3.	0.5	36
80	Costs associated with Barrett's esophagus screening in the community: an economic analysis of a prospective randomized controlled trial of sedated versus hospital unsedated versus mobile community unsedated endoscopy. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 88-94.e2.	0.5	35
81	Higher Rate of Barrett's Detection in the First Year After Successful Endoscopic Therapy: Meta-analysis. <i>American Journal of Gastroenterology</i> , 2018, 113, 959-971.	0.2	35
82	Biomarkers in Barrett Esophagus. <i>Mayo Clinic Proceedings</i> , 2001, 76, 438-446.	1.4	34
83	Photodynamic Therapy of Barrett's Esophagus. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2000, 10, 409-419.	0.6	33
84	Mucosal Ablation Therapy of Barrett Esophagus. <i>Mayo Clinic Proceedings</i> , 2001, 76, 433-437.	1.4	33
85	Outcomes of patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study. <i>Gastrointestinal Endoscopy</i> , 2020, 92, 31-39.e1.	0.5	33
86	Correlation of histology with biomarker status after photodynamic therapy in Barrett esophagus. <i>Cancer</i> , 2008, 113, 470-476.	2.0	32
87	Persistent intestinal metaplasia after endoscopic eradication therapy of neoplastic Barrett's esophagus increases the risk of dysplasia recurrence: meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 913-925.e6.	0.5	32
88	Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 361-365.	1.1	31
89	EUS-derived criteria for distinguishing benign from malignant metastatic solid hepatic masses. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 1188-1196.e7.	0.5	30
90	Outcomes of T1b esophageal adenocarcinoma patients. <i>Gastrointestinal Endoscopy</i> , 2011, 74, 1201-1206.	0.5	29

#	ARTICLE	IF	CITATIONS
91	Volumetric Laser Endomicroscopy Detects Subsquamous Barrett's Adenocarcinoma. American Journal of Gastroenterology, 2014, 109, 298-299.	0.2	29
92	Photodynamic therapy for Barrett's esophagus: does light still have a role?. Endoscopy, 2008, 40, 1021-1025.	1.0	28
93	Detection of peritoneal carcinomatosis by EUS fine-needle aspiration: impact on staging and resectability (with videos). Gastrointestinal Endoscopy, 2015, 81, 1215-1224.	0.5	28
94	Accurate Nonendoscopic Detection of Barrett's Esophagus by Methylated DNA Markers: A Multisite Case Control Study. American Journal of Gastroenterology, 2020, 115, 1201-1209.	0.2	28
95	Prospective Evaluation of Adverse Events Following Lower Gastrointestinal Tract EUS FNA. American Journal of Gastroenterology, 2014, 109, 676-685.	0.2	27
96	ASGE EndoVators Summit: simulators and the future of endoscopic training. Gastrointestinal Endoscopy, 2019, 90, 13-26.	0.5	27
97	Nonsurgical management of Barrett's esophagus with high-grade dysplasia. Surgical Oncology Clinics of North America, 2002, 11, 321-336.	0.6	25
98	Screening, Surveillance, and Prevention for Esophageal Cancer. Gastroenterology Clinics of North America, 2009, 38, 59-73.	1.0	25
99	Prediction of response to endoscopic therapy of Barrett's dysplasia by using genetic biomarkers. Gastrointestinal Endoscopy, 2014, 80, 984-991.	0.5	25
100	Remote malignant intravascular thrombi: EUS-guided FNA diagnosis and impact on cancer staging. Gastrointestinal Endoscopy, 2017, 86, 150-155.	0.5	25
101	Predictors of Progression in Barrett's Esophagus with Low-Grade Dysplasia: Results from a Multicenter Prospective BE Registry. American Journal of Gastroenterology, 2017, 112, 867-873.	0.2	25
102	Frozen Section Analysis of Esophageal Endoscopic Mucosal Resection Specimens in the Real-Time Management of Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2006, 4, 173-178.	2.4	23
103	Comparative Outcomes of Cap Assisted Endoscopic Resection and Endoscopic Submucosal Dissection in Dysplastic Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2022, 20, 65-73.e1.	2.4	22
104	Application of artificial intelligence using a novel EUS-based convolutional neural network model to identify and distinguish benign and malignant hepatic masses. Gastrointestinal Endoscopy, 2021, 93, 1121-1130.e1.	0.5	22
105	Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating stromal cells in the microenvironment. Journal of Biomedical Optics, 2019, 24, 1.	1.4	22
106	Wide-area transepithelial sampling for dysplasia detection in Barrett's esophagus: a systematic review and meta-analysis. Gastrointestinal Endoscopy, 2022, 95, 51-59.e7.	0.5	21
107	Prevalence and Predictors of Gastroesophageal Reflux Complications in Community Subjects. Digestive Diseases and Sciences, 2016, 61, 3221-3228.	1.1	20
108	NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targeting Heterogeneity in Cancer. Journal of Clinical Medicine, 2020, 9, 2390.	1.0	20

#	ARTICLE	IF	CITATIONS
109	Neoplasia Detection Rate in Barrett's Esophagus and Its Impact on Missed Dysplasia: Results from a Large Population-Based Database. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 922-929.e1.	2.4	20
110	Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma. <i>Human Pathology</i> , 2012, 43, 172-179.	1.1	19
111	Screening and Preventive Strategies in Esophagogastric Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 163-178.	0.6	18
112	Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett's Esophagus Screening. <i>American Journal of Gastroenterology</i> , 2021, 116, 1620-1631.	0.2	18
113	Role of mucosal ablative therapy in the treatment of the columnar-lined esophagus. <i>Chest Surgery Clinics of North America</i> , 2002, 12, 185-203.	0.8	17
114	Endoscopic Evaluation and Advanced Imaging of Barrett's Esophagus. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2011, 21, 39-51.	0.6	17
115	Pancreatic cyst epithelial denudation: a natural phenomenon in the absence of treatment. <i>Gastrointestinal Endoscopy</i> , 2016, 84, 788-793.	0.5	17
116	Persistence of Nondysplastic Barrett's Esophagus Is Not Protective Against Progression to Adenocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 950-952.	2.4	17
117	Recent Advances in Endoscopy. <i>Gastroenterology</i> , 2017, 153, 364-381.	0.6	17
118	Validation of a methylated DNA marker panel for the nonendoscopic detection of Barrett's esophagus in a multisite case-control study. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 498-505.	0.5	17
119	Limitations of Heartburn and Other Societies' Criteria in Barrett's Screening for Detecting De Novo Esophageal Adenocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1709-1718.	2.4	17
120	Complications of Photodynamic Therapy in Gastrointestinal Disease. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2000, 10, 487-495.	0.6	16
121	Mucosal Ablation Therapy of Barrett Esophagus. <i>Mayo Clinic Proceedings</i> , 2001, 76, 433-437.	1.4	15
122	Barrett's Esophagus in 2012: Updates in Pathogenesis, Treatment, and Surveillance. <i>Current Gastroenterology Reports</i> , 2013, 15, 322.	1.1	15
123	A prospective multicenter study using a new multiband mucosectomy device for endoscopic resection of early neoplasia in Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 647-654.	0.5	15
124	AGA Clinical Practice Update on the Utility of Endoscopic Submucosal Dissection in T1b Esophageal Cancer: Expert Review. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2161-2166.	2.4	15
125	Feasibility and Safety of Tethered Capsule Endomicroscopy in Patients With Barrett's Esophagus in a Multi-Center Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 756-765.e3.	2.4	15
126	Emerging Concepts for the Endoscopic Management of Superficial Esophageal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 851-860.	0.9	14



#	ARTICLE	IF	CITATIONS
127	Computer-aided diagnosis in GI endoscopy: looking into the future. <i>Gastrointestinal Endoscopy</i> , 2016, 84, 842-844.	0.5	14
128	Assessment of the diagnostic performance and interobserver variability of endocytoscopy in Barrett's esophagus: A pilot ex-vivo study. <i>World Journal of Gastroenterology</i> , 2013, 19, 8652.	1.4	13
129	Comparative outcomes of radiofrequency ablation and cryoballoon ablation in dysplastic Barrett's esophagus: a propensity score-matched cohort study. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 422-431.e2.	0.5	13
130	Mucosal Ablation in Patients with Barrett's Esophagus: Fry or Freeze?. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2129-2135.	1.1	12
131	Young Adults With Esophageal Adenocarcinoma Present With More Advanced Stage Tumors and Have Shorter Survival Times. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1756-1762.	2.4	12
132	Clinical significance of recurrent gastroesophageal junction intestinal metaplasia after endoscopic eradication of Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 1250-1257.e3.	0.5	12
133	Safety and feasibility of same-day discharge after esophageal endoscopic submucosal dissection. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 853-860.	0.5	12
134	CT radiomic features of photodynamic priming in clinical pancreatic adenocarcinoma treatment. <i>Physics in Medicine and Biology</i> , 2021, 66, 175006.	1.6	12
135	Photodynamic priming with triple-receptor targeted nanoconjugates that trigger T cell-mediated immune responses in a 3D in vitro heterocellular model of pancreatic cancer. <i>Nanophotonics</i> , 2021, 10, 3199-3214.	2.9	12
136	Current strategies in the management of Barrett's esophagus. <i>Current Gastroenterology Reports</i> , 2005, 7, 196-201.	1.1	11
137	Synergistic effects of photodynamic therapy with HPPH and gemcitabine in pancreatic cancer cell lines. <i>Lasers in Surgery and Medicine</i> , 2012, 44, 755-761.	1.1	11
138	The Risk of Endoscopic Mucosal Resection in the Setting of Clopidogrel Use. <i>ISRN Gastroenterology</i> , 2014, 2014, 1-5.	1.5	11
139	Safety, Diagnostic Accuracy, and Effects of Endoscopic Ultrasound Fine-Needle Aspiration on Detection of Extravascular Migratory Metastases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2533-2540.e1.	2.4	11
140	Detection and staging of esophageal cancers. <i>Current Opinion in Gastroenterology</i> , 2004, 20, 381-385.	1.0	10
141	Utility of baseline positron emission tomography with computed tomography for predicting endoscopic resectability and survival outcomes in patients with early esophageal adenocarcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 975-981.	1.4	10
142	Radiofrequency Ablation of Barrett's Esophagus. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2017, 27, 491-501.	0.6	10
143	Esophageal Epidermoid Metaplasia: Clinical Characteristics and Risk of Esophageal Squamous Neoplasia. <i>American Journal of Gastroenterology</i> , 2021, 116, 1533-1536.	0.2	10
144	Immature myeloid progenitors promote disease progression in a mouse model of Barrett's-like metaplasia. <i>Oncotarget</i> , 2015, 6, 32980-33005.	0.8	10

#	ARTICLE	IF	CITATIONS
145	How should Barrett's ulceration be treated?. Surgical Endoscopy and Other Interventional Techniques, 2004, 18, 338-344.	1.3	9
146	Endocytoscopy in Esophageal Cancer. Gastrointestinal Endoscopy Clinics of North America, 2009, 19, 273-281.	0.6	9
147	What Constitutes Optimal Management of T1NO Esophageal Adenocarcinoma?. Annals of Surgical Oncology, 2019, 26, 714-731.	0.7	9
148	Safety and histologic outcomes of endoscopic submucosal dissection with a novel articulating knife for esophageal neoplasia. Gastrointestinal Endoscopy, 2020, 91, 797-805.	0.5	9
149	EMR for early stage esophageal cancer: setting the stage for improved patient outcomes. Gastrointestinal Endoscopy, 2003, 58, 244-246.	0.5	8
150	MicroRNA Expression Signatures During Malignant Progression From Barrett's Esophagus. Journal of Cellular Biochemistry, 2016, 117, 1288-1295.	1.2	8
151	Cytosponge use in risk stratification of Barrett's oesophagus. The Lancet Gastroenterology and Hepatology, 2017, 2, 3-4.	3.7	8
152	Risk factors for serious adverse events associated with multiband mucosectomy in Barrett's esophagus: an international multicenter analysis of 3827 endoscopic resection procedures. Gastrointestinal Endoscopy, 2020, 92, 259-268.e2.	0.5	8
153	External validation of blue light imaging (BLI) criteria for the optical characterization of colorectal polyps by endoscopy experts. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2728-2734.	1.4	8
154	Spray cryotherapy prevents need for palliative stenting in patients with esophageal cancer-associated dysphagia. Ecological Management and Restoration, 2022, 35, .	0.2	8
155	Endoscopic Ultrasound Fine-Needle Aspiration Diagnosis of Synchronous Primary Pancreatic Adenocarcinoma and Effects on Staging and Resectability. Clinical Gastroenterology and Hepatology, 2017, 15, 299-302.e4.	2.4	7
156	Smokeless Tobacco and Cigar and/or Pipe Are Risk Factors for Barrett Esophagus in Male Patients With Gastroesophageal Reflux Disease. Mayo Clinic Proceedings, 2018, 93, 1282-1289.	1.4	7
157	Accuracy of Endoscopic Ultrasound Imaging in Distinguishing Celiac Ganglia From Celiac Lymph Nodes. Clinical Gastroenterology and Hepatology, 2019, 17, 148-155.e3.	2.4	7
158	NBI in Barrett esophagus "look more and sample less. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 250-251.	8.2	6
159	Tissue-Engineered Cell Sheets for Stricture Prevention: A New Connection Between Endoscopy and Regenerative Medicine. Gastroenterology, 2012, 143, 526-529.	0.6	6
160	319 Recurrence of Intestinal Metaplasia After Eradication of Barrett's Esophagus With Radio Frequency Ablation - Results From a BETRNet Consortium. Gastroenterology, 2012, 142, S-73.	0.6	6
161	Volumetric laser endomicroscopy interpretation and feature analysis in dysplastic Barrett's esophagus. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1761-1765.	1.4	6
162	Outcome of endoscopic mucosal resection in Barrett's esophagus determined by systematic quantification of epithelial glands using volumetric laser endomicroscopy. Gastrointestinal Endoscopy, 2019, 89, 701-708.e1.	0.5	6

#	ARTICLE	IF	CITATIONS
163	Rio de Janeiro Global Consensus on Landmarks, Definitions, and Classifications in Barrett's Esophagus: World Endoscopy Organization Delphi Study. <i>Gastroenterology</i> , 2022, 163, 84-96.e2.	0.6	6
164	Endoscopic mucosal resection: Esophageal applications. <i>Current Treatment Options in Gastroenterology</i> , 2005, 8, 41-49.	0.3	5
165	Barrett's Esophagus Translational Research Network (BETRNet): The Pivotal Role of Multi-institutional Collaboration in Esophageal Adenocarcinoma Research. <i>Gastroenterology</i> , 2014, 146, 1586-1590.	0.6	5
166	Esophagectomy Outcomes in the Endoscopic Mucosal Resection Era. <i>Annals of Thoracic Surgery</i> , 2017, 103, 890-897.	0.7	5
167	Editorial: The Effect of Bias on Estimation of Improved Survival After Diagnosis of Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2017, 112, 1265-1266.	0.2	5
168	Esophageal Leukoplakia. <i>ACG Case Reports Journal</i> , 2019, 6, e00213.	0.2	5
169	Comparison of Phenotypes and Risk Factors for Esophageal Adenocarcinoma at Present vs Prior Decades. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2710-2716.e1.	2.4	5
170	Impact of bariatric surgery on surveillance and treatment outcomes of Barrett's esophagus: A stage-matched cohort study. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, 1457-1464.	1.0	5
171	<title>Laser-induced fluorescence in the detection of esophageal carcinoma</title>. , 1995, 2324, 14.		4
172	Management of Barrett's esophagus with high-grade dysplasia. <i>Surgical Clinics of North America</i> , 2002, 82, 683-695.	0.5	4
173	299 Detection of Barrett's Esophagus by Non-invasive Breath Screening of Exhaled Volatile Organic Compounds Using an Electronic-Nose Device. <i>Gastroenterology</i> , 2016, 150, S67.	0.6	4
174	Outcomes of radiofrequency ablation by manual versus self-sizing circumferential balloon catheters for the treatment of dysplastic Barrett's esophagus: a multicenter comparative cohort study. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 880-887.e1.	0.5	4
175	Expert assessment on volumetric laser endomicroscopy full scans in Barrett's esophagus patients with or without high grade dysplasia or early cancer. <i>Endoscopy</i> , 2021, 53, 218-225.	1.0	4
176	Optimized Surveillance Intervals Following Endoscopic Eradication of Dysplastic Barrett's Esophagus: An International Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2763-2771.e3.	2.4	4
177	Combined Endoscopic Mucosal Resection and Photodynamic Therapy for High-Grade Dysplasia and Early Cancer in Barrett's Esophagus. <i>Techniques in Gastrointestinal Endoscopy</i> , 2005, 7, 69-72.	0.3	3
178	Endoscopic Treatment for Barrett's Esophagus and Early Esophageal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 946-947.	0.9	3
179	Tu1120 Obstructive Sleep Apnea is a Risk Factor for Barrett's Esophagus. <i>Gastroenterology</i> , 2012, 142, S-751-S-752.	0.6	3
180	Tu1094 Physician Satisfaction With Current Barrett's Esophagus Surveillance and Acceptability of FISH-Based Testing: A Survey of Gastroenterologists Across the United States. <i>Gastroenterology</i> , 2012, 142, S-744.	0.6	3

#	ARTICLE	IF	CITATIONS
181	Medical and endoscopic management of high-grade dysplasia in Barrett's esophagus. <i>Ecological Management and Restoration</i> , 2012, 25, 349-355.	0.2	3
182	A novel method to prevent catheter dysfunction during spray cryotherapy. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 889-890.	0.5	3
183	Screening for Barrett's esophagus. <i>Minerva Medica</i> , 2017, 108, 28-42.	0.3	3
184	Risk Factor Profiles Can Distinguish Esophageal Adenocarcinoma From Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2021, 116, 198-201.	0.2	3
185	Photoablation of Barrett's esophagus. <i>Journal of Gastrointestinal Surgery</i> , 2000, 4, 344-345.	0.9	2
186	Endoscopic vs Surgical Resection for Barrett's Intramucosal Adenocarcinoma: Beyond a Therapeutic Equipoise. <i>Gastroenterology</i> , 2012, 143, 257-259.	0.6	2
187	Risk stratification and surveillance in Barrett oesophagus. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 82-84.	8.2	2
188	Editorial: Shining a New Narrow Band of Light on Old Problems. <i>American Journal of Gastroenterology</i> , 2014, 109, 864-866.	0.2	2
189	Longitudinal and Circumferential Distributions of Dysplasia and Early Neoplasia in Barrett's Esophagus: A Pooled Analysis of Three Prospective Studies. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00311.	1.3	2
190	Endoscopic submucosal dissection and potential cancer dissemination. <i>Gut</i> , 2022, 71, 236-237.	6.1	2
191	Cryotherapy for Persistent Barrett's Dysplasia after Radiofrequency Ablation: If You Can't Burn It, Freeze It!. <i>American Journal of Gastroenterology</i> , 2012, 107, S26-S27.	0.2	2
192	Gene expression profiles of esophageal squamous cell cancers in Hodgkin lymphoma survivors versus sporadic cases. <i>PLoS ONE</i> , 2020, 15, e0243178.	1.1	2
193	Dramatic Reduction of Distant Pancreatic Metastases Using Local Light Activation of Verteporfin with Nab-Paclitaxel. <i>Cancers</i> , 2021, 13, 5781.	1.7	2
194	Spray cryotherapy versus continued radiofrequency ablation in persistent Barrett's esophagus. <i>Ecological Management and Restoration</i> , 2022, , .	0.2	2
195	Multimodality Therapy for Gastroesophageal Cancers, ,. <i>Journal of Gastrointestinal Surgery</i> , 2002, 6, 527-531.	0.9	1
196	Esophageal Adenocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1221-1224.	2.4	1
197	Preface. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2009, 19, xiii-xiv.	0.6	1
198	Ablation Is in the Eye of the Beholder. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 643-644.	2.4	1

#	ARTICLE	IF	CITATIONS
199	The Efficacy of Screening Colonoscopy. JAMA Internal Medicine, 2014, 174, 483.	2.6	1
200	Use of volumetric laser endomicroscopy to characterize a duodenal neuroendocrine tumor. Gastrointestinal Endoscopy, 2018, 87, 894-895.	0.5	1
201	Staging of T1 esophageal adenocarcinoma with volumetric laser endomicroscopy: a feasibility study. Endoscopy International Open, 2019, 07, E462-E470.	0.9	1
202	Clinical impact of celiac ganglia metastasis upon pancreatic ductal adenocarcinoma. Pancreatology, 2020, 20, 110-115.	0.5	1
203	Finding Barrett's oesophagus: is there a machine learning approach in our future?. The Lancet Digital Health, 2020, 2, e6-e7.	5.9	1
204	Scissor-type knife improves the safety of endoscopic submucosal dissection (ESD) among endoscopists without experience in ESD: a randomized ex vivo study. Endoscopy International Open, 2021, 09, E1207-E1213.	0.9	1
205	Surveillance and screening for Barrett's esophagus: What to do when we have so many patients and so little evidence. ASGE Clinical Update, 2005, 13, 1-4.	0.5	0
206	A novel endoscopic oids system for non-invasive early diagnosis of esophageal cancers. , 2009, , .		0
207	The essence of management of Barrett's esophagus. Gastrointestinal Endoscopy, 2013, 78, 702-703.	0.5	0
208	Cancer diagnostics: Light scattering by pancreatic cysts. Nature Biomedical Engineering, 2017, 1, .	11.6	0
209	Screening patients for Barrett esophagus: Why, who, and how. Techniques in Gastrointestinal Endoscopy, 2018, 20, 55-61.	0.3	0
210	Response:. Gastrointestinal Endoscopy, 2018, 87, 1595.	0.5	0
211	Endoscopic Treatment of Early Esophageal Neoplasia. , 2019, , 302-315.e2.		0
212	Screening for Barrett's oesophagus: is now the time?. Lancet, The, 2020, 396, 292-293.	6.3	0
213	Diagnostic performance of volumetric laser endomicroscopy for Barrett's esophagus dysplasia amongst gastroenterology trainees. Translational Gastroenterology and Hepatology, 2022, 7, 0-0.	1.5	0
214	Endoscopic Management of Pre-invasive Esophageal Adenocarcinoma. , 2011, , 227-244.		0
215	Endoscopic Treatment of Superficial Esophageal Cancers. , 2012, , 340-349.		0
216	Inhibition of the BMP pathway prevents development of Barrett's-associated adenocarcinoma in a surgical rat model. Ecological Management and Restoration, 2021, , .	0.2	0

#	ARTICLE	IF	CITATIONS
217	How I Treat Patients With Barrett Esophagus When Endoscopic Ablation Fails. Gastroenterology and Hepatology, 2020, 16, 82-87.	0.2	0